Showing 8061-8070 of 8647 results for "".
- GenSight Biologics Reports Findings From Studies Highlighting Benefits From Lumevoq Compared to LHON Natural Historyhttps://modernod.com/news/gensight-biologics-reports-findings-from-studies-highlighting-benefits-from-lumevoq-compared-to-lhon-natural-history/2477163/GenSight Biologics reported results from the REALITY registry study and an analysis of REVERSE and RESCUE phase 3 data, which further highlight the poor prognosis for patients with loss of vision due to Leber Hereditary Optic Neuropathy (LHON) associated with the ND4 mutation. The results
- Bausch + Lomb Introduces Envista Toric MX60ET IOL With Stableflex Technologyhttps://modernod.com/news/bausch-lomb-introduces-envista-toric-mx60et-iol-with-stableflex-technology/2477160/Bausch + Lomb has introduced the enVista toric MX60ET hydrophobic acrylic IOL with StableFlex technology. Bausch + Lomb says the MX60ET provides improved material properties to deliver enhanced optic recovery following delivery. Like the enVista toric MX60T, the MX60ET offers a glistening free op
- Joel Leftwich Named Executive Director of William L. Hudson BVI Workforce Innovation Centerhttps://modernod.com/news/joel-leftwich-named-executive-director-of-william-l-hudson-bvi-workforce-innovation-orkforce-innovation-center/2477155/Envision announced today that Joel Leftwich has been named executive director of the William L. Hudson BVI Workforce Innovation Center. The mission of the center, which is based out of Envision’s Wichita, Kansas headquarters, is to train and employ individuals with visual impairments, place them
- ImprimisRx’s FDA-Registered Outsourcing Facility Issued California Licensehttps://modernod.com/news/imprimisrxs-fda-registered-outsourcing-facility-issued-california-license/2477158/ImprimisRx announced that on December 9, 2019, its FDA-registered 503B outsourcing facility received a non-resident operating license and has now begun shipping into California. This license allows California-based ophthalmologists, optometrists, surgery centers and hospitals to order and stock I
- BVI Expands Vitreoretinal Surgery Presencehttps://modernod.com/news/bvi-expands-vitreoretinal-surgery-presence/2477146/BVI announced it has acquired Arcadophtha SARL (Arcad), a France-based ophthalmic company specializing in silicon oils, gases, and perfluorocarbons used in vitreoretinal surgery. Growth of the Arcad products will be accelerated through BVI’s commercial infra
- Quick Eye Test May Flag Unrecognized Brain Injuryhttps://modernod.com/news/quick-eye-test-may-flag-unrecognized-brain-injury/2477145/A quick, noninvasive, handheld device that detects changes in pupil size may offer rapid assessment of potential brain injury in young athletes who have sustained a high-impact hit to the head but who exhibit no obvious signs of brain injury, according to a
- New Consensus Recommendations Guide Sjogren’s Syndrome Managementhttps://modernod.com/news/new-consensus-recommendations-guide-sjogrens-syndrome-management/2477140/New consensus-based recommendations from the European League Against Rheumatism (EULAR) address the management of Sjogren’s syndrome with topical and systemic therapies, according to a Reuters report. Sjogren’s syndrome
- Limelight Bio Emerges with $75 Million to Develop Next Generation Gene Therapieshttps://modernod.com/news/limelight-bio-emerges-with-75-million-to-develop-next-generation-gene-therapies/2477141/Limelight Bio, a privately held, multi-platform, multi-disease biopharmaceutical company developing novel gene therapies, raised $75 million in new financing funded by Apple Tree Partners (ATP), a life sciences innovation fund. Founded in 2017, Limelight Bio has developed proprietary technologies
- RightEye Vision System Receives Breakthrough Device Designation from the FDA for Parkinson’s Disease Testhttps://modernod.com/news/righteye-vision-system-receives-breakthrough-device-designation-from-the-fda-for-parkinsons-disease-test/2477133/RightEye announced that the RightEye Vision System has received breakthrough device designation from the FDA for a Parkinson’s Disease Test. The designation is designed to streamline the market clearance
- Positive Phase 3 Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in NEJMhttps://modernod.com/news/positive-phase-3-results-for-genentechs-satralizumab-in-neuromyelitis-optica-spectrum-disorder-published-in-nejm/2477130/Genentech announced that data from SAkuraSky, a pivotal phase 3 study of the investigational medicine satralizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD), were published in the November 27, 2019 online issue of the New England Journal of Medicine (NEJM).